GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » InhaleRx Ltd (ASX:IRX) » Definitions » Return-on-Tangible-Asset

InhaleRx (ASX:IRX) Return-on-Tangible-Asset : -145.90% (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is InhaleRx Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. InhaleRx's annualized Net Income for the quarter that ended in Dec. 2024 was A$-0.94 Mil. InhaleRx's average total tangible assets for the quarter that ended in Dec. 2024 was A$0.65 Mil. Therefore, InhaleRx's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2024 was -145.90%.

The historical rank and industry rank for InhaleRx's Return-on-Tangible-Asset or its related term are showing as below:

ASX:IRX' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -140.4   Med: -73.84   Max: -42.81
Current: -126.44

During the past 9 years, InhaleRx's highest Return-on-Tangible-Asset was -42.81%. The lowest was -140.40%. And the median was -73.84%.

ASX:IRX's Return-on-Tangible-Asset is ranked worse than
90.45% of 869 companies
in the Medical Devices & Instruments industry
Industry Median: -1.24 vs ASX:IRX: -126.44

InhaleRx Return-on-Tangible-Asset Historical Data

The historical data trend for InhaleRx's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InhaleRx Return-on-Tangible-Asset Chart

InhaleRx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only -76.02 -45.86 -72.77 -74.90 -105.64

InhaleRx Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -89.07 -167.73 -2.82 -136.73 -145.90

Competitive Comparison of InhaleRx's Return-on-Tangible-Asset

For the Medical Devices subindustry, InhaleRx's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InhaleRx's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, InhaleRx's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where InhaleRx's Return-on-Tangible-Asset falls into.


;
;

InhaleRx Return-on-Tangible-Asset Calculation

InhaleRx's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-1.209/( (1.577+0.712)/ 2 )
=-1.209/1.1445
=-105.64 %

InhaleRx's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=-0.944/( (0.582+0.712)/ 2 )
=-0.944/0.647
=-145.90 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2024) net income data.


InhaleRx  (ASX:IRX) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


InhaleRx Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of InhaleRx's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


InhaleRx Business Description

Traded in Other Exchanges
N/A
Address
C/- Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
InhaleRx Ltd is an Australian biotechnology company specialising in precision medicine delivered through inhalation. Its novel drug device combinations target the treatment of BTcP and PD to help improve the quality of life of sufferers of these diseases. The medications are being developed to be delivered via a pressurised metered dose inhaler (pMDI) in a fixed dose, providing a convenient and effective mode of administration. The company's clinical pipeline comprises IRX211, a THC-based synthetic cannabinoid derived drug (dronabinol) delivered via a pMDI in a fixed dose designed to provide rapid onset analgesia for patients suffering from acute episodic bursts of breakthrough pain; and IRX616a, for the treatment of panic disorders.

InhaleRx Headlines

No Headlines